Key result
This editorial discusses the role of platelet progenitors and megakaryocytes in haemostasis, and how their features may explain the differential effects of antiplatelet drugs.
Key points are not available for this paper at this time.
Design
Editorial
Answers are grounded in this paper and cite their sources.
This editorial highlights the role of platelet progenitors and immature platelets in modulating the response to antiplatelet therapies such as ticagrelor and prasugrel.
This editorial refers to ‘Impact of immature platelets on platelet response to ticagrelor and prasugrel in patients with acute coronary syndrome’, by I. Bernlochner et al ., doi:10.1093/eurheartj/ehv326. Platelets are central players in haemostasis and atherothrombosis.1 Their nucleated progenitors, the megakaryocytes (MKs), reside in the bone marrow and have unique features. During differentiation, MKs first undergo a series of endomitoses, accumulating DNA up to 64–128n in a single cell; thus, mature MKs are the largest bone marrow cells, with a characteristic hyperthrophic nucleus and oversized cytoplasm ( Figure 1 ).2 Once endomitoses are completed, MKs proceed to their final, ‘suicidal’ maturation, whereby all the cytoplasm is progressively converted into pro-platelets, through pseudopod formation, elongation into the bone marrow sinusoids, and pro-platelet packaging2 ( Figure 1 ). Pre-platelets are then released as large, round, anucleated MK fragments which undergo a final binary division to discoid, mature platelets. The newly formed platelets that enter the peripheral blood have peculiar morphological and functional features: they represent the largest platelets, rich in RNA [therefore also designated ‘reticulated platelets’ (RPs)]2 and display a maximal pro-haemostatic capacity.2 Figure 1 The differential effects of antiplatelet drugs may be explained by differences in pharmacokinetics of the active moiety, and the mechanism of inactivation and variable renewal rate of the drug target. ( A ) The 24-h plasma concentrations of ticagrelor after a loading dose of 180 mg (upper panel: redrawn from Husted et al. 8), prasugrel active metabolite after a loading dose of 60 mg (middle panel: redrawn from Jakubowski et al. 7), and acetylsalicylic acid after the first dose of enteric-coated aspirin 100 mg (lower panel: redrawn from Patrignani et al. 6). The vertical black …
No takes yet. Share an insight, caveat, or question.
Bianca Rocca (2015) reported an editorial. This editorial discusses the role of platelet progenitors and megakaryocytes in haemostasis, and how their features may explain the differential effects of antiplatelet drugs.
Synapse has enriched 10 related papers. Consider them for comparative context: